250 related articles for article (PubMed ID: 23745696)
1. Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: comparison with adrenomedullin and CGRP.
Holmes D; Campbell M; Harbinson M; Bell D
Curr Protein Pept Sci; 2013 Jun; 14(4):294-329. PubMed ID: 23745696
[TBL] [Abstract][Full Text] [Related]
2. Structure-function analyses reveal a triple β-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design.
Roehrkasse AM; Booe JM; Lee SM; Warner ML; Pioszak AA
J Biol Chem; 2018 Oct; 293(41):15840-15854. PubMed ID: 30139742
[TBL] [Abstract][Full Text] [Related]
3. Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin
Babin KM; Karim JA; Gordon PH; Lennon J; Dickson A; Pioszak AA
J Biol Chem; 2023 Jun; 299(6):104785. PubMed ID: 37146967
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.
Takahashi K; Morimoto R; Hirose T; Satoh F; Totsune K
J Mol Neurosci; 2011 Feb; 43(2):182-92. PubMed ID: 20596793
[TBL] [Abstract][Full Text] [Related]
5. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.
Bell D; McDermott BJ
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S247-62. PubMed ID: 17965749
[TBL] [Abstract][Full Text] [Related]
6. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake.
Taylor MM; Bagley SL; Samson WK
Am J Physiol Regul Integr Comp Physiol; 2005 Apr; 288(4):R919-27. PubMed ID: 15576658
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-derived intermedin/adrenomedullin-2 protects human ventricular cardiomyocytes from ischaemia-reoxygenation injury predominantly via the AM₁ receptor.
Bell D; Campbell M; McAleer SF; Ferguson M; Donaghy L; Harbinson MT
Peptides; 2016 Feb; 76():1-13. PubMed ID: 26743504
[TBL] [Abstract][Full Text] [Related]
8. Adrenomedullin - Current perspective on a peptide hormone with significant therapeutic potential.
Fischer JP; Els-Heindl S; Beck-Sickinger AG
Peptides; 2020 Sep; 131():170347. PubMed ID: 32569606
[TBL] [Abstract][Full Text] [Related]
9. Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges.
Hay DL; Walker CS; Poyner DR
Endocr Relat Cancer; 2011 Feb; 18(1):C1-14. PubMed ID: 21051558
[TBL] [Abstract][Full Text] [Related]
10. Comparing the molecular pharmacology of CGRP and adrenomedullin.
Woolley MJ; Conner AC
Curr Protein Pept Sci; 2013 Aug; 14(5):358-74. PubMed ID: 23745700
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology of adrenomedullin 2/intermedin.
Hong Y; Hay DL; Quirion R; Poyner DR
Br J Pharmacol; 2012 May; 166(1):110-20. PubMed ID: 21658025
[TBL] [Abstract][Full Text] [Related]
12. AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.
Bell D; Campbell M; Ferguson M; Sayers L; Donaghy L; O'Regan A; Jewhurst V; Harbinson M
J Physiol; 2012 Mar; 590(5):1181-97. PubMed ID: 22183724
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension.
Holmes D; Corr M; Thomas G; Harbinson M; Campbell M; Spiers P; Bell D
Peptides; 2020 Apr; 126():170267. PubMed ID: 32017948
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
Zhao Y; Bell D; Smith LR; Zhao L; Devine AB; McHenry EM; Nicholls DP; McDermott BJ
J Pharmacol Exp Ther; 2006 Mar; 316(3):1269-81. PubMed ID: 16326922
[TBL] [Abstract][Full Text] [Related]
15. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.
Hay DL; Garelja ML; Poyner DR; Walker CS
Br J Pharmacol; 2018 Jan; 175(1):3-17. PubMed ID: 29059473
[TBL] [Abstract][Full Text] [Related]
16. Shared and separate functions of the RAMP-based adrenomedullin receptors.
Kuwasako K; Kitamura K; Nagata S; Hikosaka T; Takei Y; Kato J
Peptides; 2011 Jul; 32(7):1540-50. PubMed ID: 21645567
[TBL] [Abstract][Full Text] [Related]
17. Variable CGRP family peptide signaling durations and the structural determinants thereof.
Babin KM; Gostynska SE; Karim JA; Pioszak AA
Biochem Pharmacol; 2024 Jun; 224():116235. PubMed ID: 38670438
[TBL] [Abstract][Full Text] [Related]
18. Spatial expression of components of a calcitonin receptor-like receptor (CRL) signalling system (CRL, calcitonin gene-related peptide, adrenomedullin, adrenomedullin-2/intermedin) in mouse and human heart valves.
Pfeil U; Bharathala S; Murtaza G; Mermer P; Papadakis T; Boening A; Kummer W
Cell Tissue Res; 2016 Dec; 366(3):587-599. PubMed ID: 27553639
[TBL] [Abstract][Full Text] [Related]
19. Vascular actions of calcitonin gene-related peptide and adrenomedullin.
Brain SD; Grant AD
Physiol Rev; 2004 Jul; 84(3):903-34. PubMed ID: 15269340
[TBL] [Abstract][Full Text] [Related]
20. Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure.
Hirose T; Totsune K; Mori N; Mori T; Morimoto R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Kohzuki M; Takahashi K; Imai Y
Am J Physiol Renal Physiol; 2010 Jul; 299(1):F128-34. PubMed ID: 20462970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
